The MarketWatch News Department was not involved in the creation of this content. Cure HHT plays pivotal role in the NIH-sponsored PATH Trial becoming the first successful, large-scale randomized ...
Announced positive topline results from TX45 Phase 1b acute hemodynamic clinical trial in patients with Group 2 Pulmonary Hypertension in Heart ...
A clinical trial supported by the National Institutes of Health (NIH) was stopped early after researchers found sufficient evidence that a drug called pomalidomide, which is used to treat bone marrow ...
A drug approved for treating the blood cancer multiple myeloma may offer a safe and effective way to reduce the risk of severe nosebleeds from a rare but devastating bleeding disorder. Hereditary ...
Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the ...
Hereditary hemorrhagic telangiectasia (HHT), also known as Osler-Weber-Rendu syndrome, is a rare, but serious, genetic disorder that causes abnormal blood vessels to form throughout the body. These ...
Hypophosphataemia is a rare but serious side effect of some iron infusions. It means having low levels of phosphate in the blood, a mineral that is important for healthy bones, muscles, and energy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results